225 related articles for article (PubMed ID: 21569821)
1. Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro.
Tucci M; Ciavarella S; Strippoli S; Brunetti O; Dammacco F; Silvestris F
Exp Hematol; 2011 Jul; 39(7):773-83.e1. PubMed ID: 21569821
[TBL] [Abstract][Full Text] [Related]
2. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
Yu X; Huang Y; Collin-Osdoby P; Osdoby P
J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
[TBL] [Abstract][Full Text] [Related]
3. Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration.
Yu X; Huang Y; Collin-Osdoby P; Osdoby P
J Bone Miner Res; 2003 Aug; 18(8):1404-18. PubMed ID: 12929930
[TBL] [Abstract][Full Text] [Related]
4. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop.
Moreaux J; Sprynski AC; Dillon SR; Mahtouk K; Jourdan M; Ythier A; Moine P; Robert N; Jourdan E; Rossi JF; Klein B
Eur J Haematol; 2009 Aug; 83(2):119-29. PubMed ID: 19456850
[TBL] [Abstract][Full Text] [Related]
5. Immature dendritic cells in multiple myeloma are prone to osteoclast-like differentiation through interleukin-17A stimulation.
Tucci M; Stucci S; Savonarola A; Ciavarella S; Cafforio P; Dammacco F; Silvestris F
Br J Haematol; 2013 Jun; 161(6):821-31. PubMed ID: 23594390
[TBL] [Abstract][Full Text] [Related]
6. Stromal cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts.
Wright LM; Maloney W; Yu X; Kindle L; Collin-Osdoby P; Osdoby P
Bone; 2005 May; 36(5):840-53. PubMed ID: 15794931
[TBL] [Abstract][Full Text] [Related]
7. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
[TBL] [Abstract][Full Text] [Related]
8. [Effects of the osteoclast in pathogenesis of multiple myeloma].
Zhang JH; Fu JX; Zhang XH; Sun Y
Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):323-6. PubMed ID: 17877161
[TBL] [Abstract][Full Text] [Related]
9. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
Giuliani N; Colla S; Morandi F; Rizzoli V
Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
[TBL] [Abstract][Full Text] [Related]
10. Dysregulation of the receptor activator of NF-kappaB ligand and osteoprotegerin production influence the apoptosis of multiple myeloma patients' bone marrow stromal cells co-cultured with myeloma cells.
Zdzisińska B; Bojarska-Junak A; Walter-Croneck A; Kandefer-Szerszeń M
Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):153-63. PubMed ID: 20157786
[TBL] [Abstract][Full Text] [Related]
11. Malignant B-lymphoid cells with bone lesions express receptor activator of nuclear factor-kappaB ligand and vascular endothelial growth factor to enhance osteoclastogenesis.
Shibata H; Abe M; Hiura K; Wilde J; Moriyama K; Sano T; Kitazoe K; Hashimoto T; Ozaki S; Wakatsuki S; Kido S; Inoue D; Matsumoto T
Clin Cancer Res; 2005 Sep; 11(17):6109-15. PubMed ID: 16144909
[TBL] [Abstract][Full Text] [Related]
12. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
Kanazawa K; Kudo A
J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
[TBL] [Abstract][Full Text] [Related]
13. RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone.
Atkins GJ; Kostakis P; Vincent C; Farrugia AN; Houchins JP; Findlay DM; Evdokiou A; Zannettino AC
J Bone Miner Res; 2006 Sep; 21(9):1339-49. PubMed ID: 16939392
[TBL] [Abstract][Full Text] [Related]
14. Functional osteoclast-like transformation of cultured human myeloma cell lines.
Calvani N; Cafforio P; Silvestris F; Dammacco F
Br J Haematol; 2005 Sep; 130(6):926-38. PubMed ID: 16156862
[TBL] [Abstract][Full Text] [Related]
15. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
Shipman CM; Croucher PI
Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
[TBL] [Abstract][Full Text] [Related]
16. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.
Bolzoni M; Storti P; Bonomini S; Todoerti K; Guasco D; Toscani D; Agnelli L; Neri A; Rizzoli V; Giuliani N
Exp Hematol; 2013 Apr; 41(4):387-97.e1. PubMed ID: 23178378
[TBL] [Abstract][Full Text] [Related]
18. CCL9/MIP-1gamma and its receptor CCR1 are the major chemokine ligand/receptor species expressed by osteoclasts.
Lean JM; Murphy C; Fuller K; Chambers TJ
J Cell Biochem; 2002; 87(4):386-93. PubMed ID: 12397598
[TBL] [Abstract][Full Text] [Related]
19. TRAIL produced from multiple myeloma cells is associated with osteolytic markers.
Kawano Y; Ueno S; Abe M; Kikukawa Y; Yuki H; Iyama K; Okuno Y; Mitsuya H; Hata H
Oncol Rep; 2012 Jan; 27(1):39-44. PubMed ID: 21993926
[TBL] [Abstract][Full Text] [Related]
20. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
